Emergent BioSolutions, Inc. (EBS)
6.06
+0.21
(+3.59%)
USD |
NYSE |
Nov 06, 16:00
6.05
-0.01
(-0.17%)
Pre-Market: 20:00
Emergent BioSolutions Cash from Investing (Quarterly) : 4.60M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 4.60M |
| June 30, 2026 | -52.30M |
| March 31, 2026 | -2.40M |
| December 31, 2025 | -3.90M |
| September 30, 2025 | -3.40M |
| June 30, 2025 | 17.20M |
| March 31, 2025 | 59.50M |
| December 31, 2024 | 28.60M |
| September 30, 2024 | 112.00M |
| June 30, 2024 | -4.60M |
| March 31, 2024 | -10.80M |
| December 31, 2023 | -11.40M |
| September 30, 2023 | -18.90M |
| June 30, 2023 | 257.70M |
| March 31, 2023 | -15.10M |
| December 31, 2022 | -45.40M |
| September 30, 2022 | -271.60M |
| June 30, 2022 | -32.10M |
| March 31, 2022 | -32.20M |
| December 31, 2021 | -45.80M |
| September 30, 2021 | -55.20M |
| June 30, 2021 | -67.00M |
| March 31, 2021 | -56.10M |
| December 31, 2020 | -36.00M |
| September 30, 2020 | -45.70M |
| Date | Value |
|---|---|
| June 30, 2020 | -45.10M |
| March 31, 2020 | -24.20M |
| December 31, 2019 | -36.10M |
| September 30, 2019 | -15.30M |
| June 30, 2019 | -24.10M |
| March 31, 2019 | -21.40M |
| December 31, 2018 | -848.55M |
| September 30, 2018 | -26.06M |
| June 30, 2018 | -10.98M |
| March 31, 2018 | -11.62M |
| December 31, 2017 | -207.55M |
| September 30, 2017 | -12.78M |
| June 30, 2017 | -9.301M |
| March 31, 2017 | -20.30M |
| December 31, 2016 | -20.01M |
| September 30, 2016 | -17.00M |
| June 30, 2016 | -21.03M |
| March 31, 2016 | -18.21M |
| December 31, 2015 | -11.83M |
| September 30, 2015 | -13.95M |
| June 30, 2015 | -10.60M |
| March 31, 2015 | -9.082M |
| December 31, 2014 | -17.26M |
| September 30, 2014 | -5.221M |
| June 30, 2014 | -4.81M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | -6.101B |
| Arcturus Therapeutics Holdings, Inc. | 0.0193M |
| Capricor Therapeutics, Inc. | -48.76M |
| Travere Therapeutics, Inc. | -119.63M |
| Syndax Pharmaceuticals, Inc. | -176.47M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 100.10M |
| Cash from Financing (Quarterly) | -68.70M |
| Free Cash Flow | 188.40M |
| Free Cash Flow Per Share (Quarterly) | 1.887 |
| Free Cash Flow to Equity (Quarterly) | 171.30M |
| Free Cash Flow to Firm (Quarterly) | 105.51M |
| Free Cash Flow Yield | 58.71% |